enGene Therapeutics (ENGN) JMP Hematology and Oncology Summit 2024 summary

Market opportunity and disease landscape

• High-risk non-muscle invasive bladder cancer (NMIBC) affects about 730,000 patients annually in the US, with significant healthcare costs and unmet needs.

• The NMIBC market is projected to exceed $20 billion by 2040, driven by the need for alternatives to radical cystectomy and evolving treatment paradigms.

• Standard of care includes BCG immunotherapy, which faces chronic shortages and high recurrence rates, and radical cystectomy, a life-altering surgery.

• Most NMIBC care is managed by community urologists, emphasizing the need for user-friendly therapies.

• New therapies aim to extend time before surgery and allow multiple lines of treatment, shifting the paradigm to a prevalence-based model.

Product profile and clinical development

• Detalimogene voraplasmid is a non-viral gene therapy with promising efficacy and a favorable safety profile, designed for ease of use by physicians and patients.

• The LEGEND study targets BCG-unresponsive NMIBC with CIS, with additional cohorts for BCG-naive, BCG-exposed, and papillary-only disease.

• September data showed a 71% complete response rate at any time, 67% at three months, and 47% at six months, with only grade 1 or 2 adverse events.

• Protocol amendments include mandatory re-resection for T1 lesions, re-induction for certain recurrences, and biopsy confirmation at six months to align with evolving standards.

• Next interim data update is expected in 2025, with confidence that protocol changes will further improve outcomes.

Competitive positioning and differentiation

• Detalimogene voraplasmid compares favorably to approved therapies (Keytruda, Adstiladrin, Anktiva) in early efficacy and safety, with no discontinuations due to adverse events.

• Product offers logistical advantages: refrigerator storage, simple reconstitution, no special handling, and shorter dwell time than BCG.

• Dosing frequency is reduced compared to BCG, with a four-time induction schedule, making it less burdensome for patients.

• Community urologists are engaged in development and advisory roles, expressing enthusiasm for the therapy’s potential impact.

• Additional cohorts in the LEGEND study will broaden the evidence base across NMIBC subtypes, supporting future positioning.